Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED)
- Conditions
- Parkinson Disease
- Interventions
- Other: Speaking TherapyOther: Therapeutic education workshop
- Registration Number
- NCT04228523
- Lead Sponsor
- University Hospital, Toulouse
- Brief Summary
Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management. This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group.
- Detailed Description
Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management.
The therapeutic educational program ETPARK includes individual's consults or workshop. The team frequently offer to patients to participate in workshop on Parkinson disease's drug.
This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group (speaking group) at 1 and 3 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
- Patients with Parkinson's disease according to the United Kingdom Parkinson Disease Society Brain Bank (UKPDSBB) criteria,
- Patients who are already in therapeutic education program ETPARK,
- Patients who need and want to participate in therapeutic education workshop on Parkinson disease drug,
- Patients with health insurance,
- Patients who have signed a written informed consent form.
- Patients suffering from another parkinsonian syndrome (multiple system atrophy, progressive supranuclear palsy etc.),
- Patients who has already done workshop on Parkinson disease drug (program ETPARK)
- Patients already included in clinical trial during the study,
- Patients who have severe psychiatric disorders or dopaminergic psychosis,
- Patients with cognitive impairment,
- Patients unable to complete the various scales used in the study,
- Patients under juridical protection,
- Women pregnant or breastfeeding.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Speaking Therapy Speaking Therapy One group receive speaking therapy already existing in Toulouse University Hospital Therapeutic education workshop Therapeutic education workshop Two group receive therapeutic education workshop already existing in Toulouse University Hospital
- Primary Outcome Measures
Name Time Method Evolution of Drug representation in Patients : BMQ Three months Evolution of Drug representation through the Believe about Medicines Questionnaire (BMQ) compared to the control group. Evolution will be compared between the Baseline and the end of the study
BMQ with eighteen items coded from 1 " "strongly agree" to 5 "strongly disagree".Evolution of Drug representation in Patients : Verbal association Three months Evolution of Drug representation through verbal association tasks compared to the control group. Evolution will be compared between the Baseline and the end of the study
- Secondary Outcome Measures
Name Time Method Knowledge about the disease three months Evolution between Baseline and three months with a test created for the study. The test have 8 questions with two answers possible : True or False
Evolution in life quality : VAS three months Evolution in life quality evaluate with Visual Analog Scale (VAS), 0 being the worst quality of life and 10 the best quality of life he can have.
Evolution between Baseline and three monthsDrug representation in caregivers : Verbal association Day 1 Drug representation through verbal association tasks.
Drug representation in caregivers : BMQ Day 1 Drug representation through the Believe about Medicines Questionnaire (BMQ). BMQ with eighteen items coded from 1 " "strongly agree" to 5 "strongly disagree".
Evolution in life quality : PDQ-(39) three months Evolution in life quality evaluate with Parkinson Disease Quotation (PDQ)-39 with thirty-nine items coded from 1 " "always" to 5 "never". The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living including relationships, social situations and communication.
Evolution between Baseline and three months
Trial Locations
- Locations (1)
Toulouse University Hospital
🇫🇷Toulouse, Occitanie, France